# A Study of TAS1440 With ATRA in Subjects With r/r AML

> **NCT04282668** · PHASE1 · TERMINATED · sponsor: **Taiho Oncology, Inc.** · enrollment: 52 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** TAS1440
- **DRUG:** TAS1440 + ATRA

## Key facts

- **NCT ID:** NCT04282668
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-15
- **Primary completion:** 2024-02-12
- **Final completion:** 2024-02-12
- **Target enrollment:** 52 (ACTUAL)
- **Why stopped:** The study was terminated due to the changing treatment landscape, difficulty in enrolling eligible participants, and little likelihood of providing meaningful clinical benefit for the participants.
- **Last updated:** 2024-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04282668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04282668, "A Study of TAS1440 With ATRA in Subjects With r/r AML". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04282668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*